Dengue

Tantawichien, Terapong; Thisayakorn, Usa

doi:10.1007/978-3-319-68493-2_10

Cited by 3 publications

(3 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dengue is one of the most frequent diseases caused by viral infection (Tantawichien and Thisayakorn, 2017). The dengue virus (DENVs) transmission relies on the vector mosquitoes, primarily the female mosquitoes of Aedes aegypti or with the less common vector of the Aedes albopictus.…”

Section: Introductionmentioning

confidence: 99%

“…According to World Health Organization (WHO), the number of dengue cases globally has risen dramatically in recent years. Dengue is endemic in more than 140 countries around, mainly affecting 2.5 billion people in the tropical and subtropical regions, including Indonesia (Tantawichien and Thisayakorn, 2017). Based on WHO (2009) guidelines, dengue disease severity can be categorized into dengue with or without warning signs and severe dengue.…”

Section: Introductionmentioning

confidence: 99%

“…However, there are some controversies that revolve around this vaccine, as Dengvaxia administration might increase people with a more severe form of dengue and the protective effects only apply to people who have had dengue before. Hence, people rely on supportive care such as antipyretics for fever, oral hydration, administration of fluids, blood/platelets/fresh frozen transfusion for patients with thrombocytopenia or hemorrhage (Schaefer et al, 2021;Tantawichien and Thisayakorn, 2017). Therefore, there is still a need to find compounds that have antiviral activity against DENV infection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Flavonoids as potential inhibitors of dengue virus 2 (DENV2) envelope protein

Renantha¹,

Liga²,

Tanugroho³

et al. 2022

J Pharm Pharmacogn Res

View full text Add to dashboard Cite

Context: Dengue viruses (DENVs) are the cause of dengue disease, which is one of the most frequent diseases caused by mosquito-borne viral infections. Currently, no specific treatment is available for dengue. Aims: To identify the most promising inhibitors of dengue virus 2 (DENV2) envelope protein of DENV2 envelope protein from flavonoids compounds through computational methods. Methods: Structures of 54 flavonoids were collected, then the compounds were screened based on Lipinski’s rules, and there were only 34 compounds that passed the screening. Then QSAR analysis was performed, followed by molecular docking analysis, ADMET evaluation, and molecular dynamics simulations to assess the stability of the protein. Results: Based on the QSAR analysis, only 32 compounds were subjected to molecular docking analysis. Silymarin had the highest docking score, while juglanin had the lowest ACE score compared to positive controls. The ADMET evaluation showed silymarin and juglanin had good absorption and could not penetrate the blood-brain barrier. In contrast to silymarin which had negative results for the Ames test, carcinogenicity, skin sensitization, and eye irritation, juglanin was positive for Ames test and skin sensitization. Even though the molecular dynamic simulation of both ligands with DENV2 envelope protein showed unstable confirmation, it did not necessarily mean that the ligands cannot be used as inhibitors since the molecular docking results provide evidence of the ligands binding to the DENV2 envelope protein. Conclusions: Based on the favorable results of QSAR analysis, molecular docking, and ADMET evaluation, juglanin and silymarin were chosen as the candidate with the most potential for DENV2 envelope protein inhibitors. However, further analyses such as in vitro and in vivo analyses are necessary to validate the result of this study.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Flavonoids as potential inhibitors of dengue virus 2 (DENV2) envelope protein

Renantha¹,

Liga²,

Tanugroho³

et al. 2022

J Pharm Pharmacogn Res

View full text Add to dashboard Cite

show abstract

Post-dengue mucormycosis- a novel entity or COVID-19 associated in disguise?

Popli,

Gupta,

Singh

et al. 2024

Trop Doct

View full text Add to dashboard Cite

Dengue is a disease endemic to tropical countries such as India. In the past two years, cases of COVID-19 associated Mucormycosis have become a commonly encountered phenomenon. However, cases of dengue associated Mucormycosis have not found a significant mention in the literature yet. We, therefore, report two such cases in which Mucormycosis developed after recovery from Dengue fever and try to dig into the possible mechanism behind such an occurrence.

show abstract

The Incidence and Characteristics of Misdiagnosed Covid-19 Patients with Dengue Fever Infections at Udayana University Hospital in 2020-2021

Adiputra,

Swastika,

Diarthini

et al. 2023

IJTID

View full text Add to dashboard Cite

The rise in dengue fever in recent decades combined with the emergence of COVID-19 at the end of 2019, has created new challenges in the healthcare sector. This research is a descriptive study with a cross-sectional research design and using medical record data at Udayana University Hospital in 2020–2021. According to the study, 1.22% cases of misdiagnosis out of a total of 2365 suspected cases of COVID-19 were found at Udayana University. The majority of cases of misdiagnosis involved people older than 60 years, namely 7 people (24.1%) and were dominated by men, namely 17 people (58.6%). The most common symptoms found are fever, cough, shortness of breath, headache, and malaise, According to laboratory results, dominant patients have thrombocytopenia, followed by high alanine transaminase (ALT), high aspartate transaminase (AST), and leukopenia. The appearance of thrombocytopenia in cases of COVID-19 with dengue fever is the result of suppressed platelet synthesis due to virus induction which causes bone marrow suppression and platelet clearance. Leukopenia and leukocytosis may coexist with lymphopenia as an indicator of disease severity. The similarity of symptoms and laboratory results between COVID-19 and dengue fever allows for misdiagnosis that will affect the patient's management. Therefore, the aim of this study is to determine the misdiagnosis rate of COVID-19 with dengue fever at Udayana University Hospital in 2020–2021, so that it can reduce misdiagnosis of the disease.

show abstract

Dengue

Cited by 3 publications

References 108 publications

Flavonoids as potential inhibitors of dengue virus 2 (DENV2) envelope protein

Flavonoids as potential inhibitors of dengue virus 2 (DENV2) envelope protein

Post-dengue mucormycosis- a novel entity or COVID-19 associated in disguise?

The Incidence and Characteristics of Misdiagnosed Covid-19 Patients with Dengue Fever Infections at Udayana University Hospital in 2020-2021

Contact Info

Product

Resources

About